EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Adam Stenman iD, Tim Nilsson iD, Henrik Falhammar iD, C Christofer Juhlin iD

Histopathology · 2026-12 · 89 (6) · 1011-1019

DOI: 10.1111/his.70254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, online erschienen am 04.08.2026. Verfasst von Adam Stenman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Hyperaldosteronism, Cytochrome P-450 CYP11B2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stockholm County Council, Karolinska Institutet, Cancer Research Foundations of Radiumhemmet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In primary aldosteronism (PA), the HISTALDO framework classifies aldosterone‐producing lesions as ‘classical’ (solitary nodule) or ‘non‐classical’ (multinodular or diffuse) based on CYP11B2 immunohistochemistry, but interpretation is complicated by frequent micronodules, even in patients without PA. The CYP11B2 size ratio (B2R), a quantitative measure of size disproportion between CYP11B2‐positive nodules, offers an objective way to assess lesion architecture and has shown value in predicting cure versus relapse. In this study, diagnostic classification was intentionally B2R‐guided, generating a modified HISTALDO B2R system in clinical routine.

Objective

Prospective evaluation of the prognostic value of B2R‐guided classification in routine pathology and assessment of postoperative outcomes across B2R‐defined subgroups.

Methods

Specimens of 70 adrenalectomies underwent multisection CYP11B2 staining; 61 patients had at least 6 months of follow‐up (mean age 53 years, 54% were females). All had adrenal vein sampling and confirmatory testing before unilateral laparoscopic adrenalectomy. Imaging showed unilateral findings in 51%, bilateral in 8% and no detectable nodules in 41%. A B2R ≥8.1 defined classical lesions; B2R < 8.1 non‐classical. Outcomes at 6–12 months were assessed using PASO criteria, which classify biochemical and clinical success as absent, partial or complete.

Results

Biochemical cure was achieved in 95% of patients with classical B2R morphology, compared with 40% of those with non‐classical B2R morphology ( p < 0.001). Complete clinical success was also significantly more frequent in the classical B2R group than in the non‐classical group (57% versus 25%, p = 0.0235). Medication‐based measures supported these findings: patients with classic histology showed a trend towards reductions in antihypertensive medication expressed as defined daily doses (DDD) (median ΔDDD 2.83 versus 2.00, p = 0.1254), and a significantly greater reduction in potassium supplementation (median ΔDDD 1.25 versus 0.00, p < 0.001) compared to those with non‐classical histology.

Conclusions

B2R‐guided HISTALDO yields biologically distinct subgroups with clear prognostic separation. Earlier work using the original HISTALDO definition reported ~40%–45% persistent biochemical aldosteronism in non‐classical cases. Our findings reproduce this poor non‐classical outcome profile in a larger and more consistently defined B2R‐classified cohort. Importantly, incorporating B2R reduces misclassification of tumours as non‐classical when background nodularity is present despite a dominant CYP11B2‐positive lesion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperaldosteronismCytochrome P-450 CYP11B2HumansFemaleMiddle AgedMaleAdultProspective StudiesAdrenalectomyAgedPrognosis

Substanzen

Cytochrome P-450 CYP11B2

Autor:innen und Institutionen

  • Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Adam Stenman, Tim Nilsson, Henrik Falhammar, C Christofer Juhlin

Förderung

  • Stockholm County Council
  • Karolinska Institutet
  • Cancer Research Foundations of Radiumhemmet
  • Cancerfonden
  • Radiumhemmets Forskningsfonder

Zitieren

APA

Stenman, A., Nilsson, T., Falhammar, H., & Juhlin, C. C. (2026). Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine. Histopathology, 89(6), 1011-1019. https://doi.org/10.1111/his.70254

Vancouver

Stenman A, Nilsson T, Falhammar H, Juhlin CC. Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine. Histopathology. 2026;89(6):1011-1019. doi:10.1111/his.70254

BibTeX
@article{Stenman2026,
  author = {Stenman, Adam and Nilsson, Tim and Falhammar, Henrik and Juhlin, C Christofer},
  title = {Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine},
  journal = {Histopathology},
  year = {2026},
  volume = {89},
  number = {6},
  pages = {1011--1019},
  doi = {10.1111/his.70254}
}
Kostenlos starten →